NCT00078819View on ClinicalTrials.gov

Etanercept (Enbrel®) in Psoriasis - Pediatrics

PHASE3CompletedINTERVENTIONAL
Enrollment

211

Participants

Timeline

Start Date

September 8, 2004

Primary Completion Date

February 1, 2006

Study Completion Date

June 1, 2007

Conditions
Psoriasis
Interventions
DRUG

Etanercept

Etanercept 0.8 mg/kg (up to an intended dose of 50 mg) by subcutaneous injection once a week

DRUG

Placebo

Placebo matching to etanercept administered by subcutaneous injection once a week

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY

NCT00078819 - Etanercept (Enbrel®) in Psoriasis - Pediatrics | Biotech Hunter | Biotech Hunter